“Fidaxomicin Treatment for Clostridioides Difficile Infection: Restricted Usage May Worsen Outcomes, Especially in Severe or Recurrent Cases”

https://pubmed.ncbi.nlm.nih.gov/38094526

This study suggests that in patients with Clostridioides difficile infection, fidaxomicin treatment had worse outcomes due to restricted usage, potentially impacting its effectiveness, particularly for severe or recurrent cases.